Cyro von Zuben de Valega Negrão
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cyro von Zuben de Valega Negrão has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Natália Neto Pereira Cerize
Institute for Technological Research (IPT)−Bionanomanufacturing Center (BIONANO)
4 shared publications - Sandra Martha Gomes Dias
Brazilian Biosciences National Laboratory, Brazilian Center for Research in Energy and Materials, Campinas, Brazil
4 shared publications Giovanna Pastore Meneguetti
Bionanomanufacturing Center, Institute for Technological Research (IPT), 05508-901, São Paulo, São Paulo, Brazil
2 shared publicationsJoão Lucas Maehara Said dos Reis
Institute for Technological Research (IPT)−Bionanomanufacturing Center (BIONANO)
2 shared publicationsKaliandra de Almeida Gonçalves
Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy & Materials (CNPEM), 13083-970, Campinas, São Paulo, Brazil
2 shared publicationsLarissa Araujo
Bionanomanufacturing Center, Institute for Technological Research (IPT), 05508-901, São Paulo, São Paulo, Brazil
2 shared publications
Latest Publications
- Open Access
Differential Cytotoxicity of PVP-Copper Nanoparticles in Breast Cancer Cell Lines: Insights from Basal Transcriptomic Profiles
Breast cancer is a heterogeneous disease comprising molecular subtypes with distinct therapeutic vulnerabilities. Among emerging therapeutic strategies, copper-based nanoparticles have shown anticancer activity. However, whether these responses differ across breast cancer subtypes and which molecular programs underlie copper sensitivity remain poorly understood. We investigated subtype-specific responses to Polyvinylpyrrolidone-assisted copper nanoparticles (CuNP-PVP) in breast cancer cell lines and the molecular programs underlying copper adaptation. CuNP-PVP were synthesized and evaluated in luminal (MCF-7), HER2-positive (SKBR3), and triple-negative (MDA-MB-231) breast cancer cell lines, with transcriptomic analyses integrated with CCLE and TCGA-BRCA datasets. UV-Vis spectroscopy revealed a plasmon resonance band at 591 nm, while TEM showed spherical nanoparticles with an average diameter of 76.1 ± 21.0 nm. DLS indicated a larger hydrodynamic diameter, consistent with PVP coating; ζ-potential measurements showed a surface charge of −13 mV, and XPS confirmed mixed reduced and Cu(I)/Cu(II) oxidation states. Exposure to 100 μg/mL CuNP-PVP induced subtype-dependent effects on cell viability, with MCF-7 showing greater sensitivity, whereas MDA-MB-231 and SKBR3 were less affected. Baseline transcriptomic analyses revealed enrichment of oxidative stress, metabolic adaptation, and lysosomal programs in less sensitive cells, whereas MCF-7 showed higher expression of lipoylation-related genes. These features supported the development of a Potential Biological Copper-Response Index (PBCRI), which captured subtype-associated transcriptional patterns across independent cell lines and patient tumors, with luminal models showing lower scores and basal/TNBC models showing higher scores. Together, these findings identify candidate transcriptional programs associated with subtype-specific responses to CuNP and provide a framework for investigating potential molecular determinants of copper sensitivity. Highlights: PVP-assisted copper nanoparticles showed mixed metallic/oxidized Cu phases. CuNP-PVP induced cell-dependent cytotoxicity in breast cancer cells. MCF-7 cells were more sensitive to CuNP-PVP than TNBC and HER2+ cells. Baseline profiles differed in lipoylation, antioxidant, and lysosomal programs. PBCRI captured subtype-associated copper-response transcriptional patterns.
Open AccessDifferential Cytotoxicity of PVP-Copper Nanoparticles in Breast Cancer Cell Lines: Insights from Basal Transcriptomic Profiles
Breast cancer is a heterogeneous disease comprising molecular subtypes with distinct therapeutic vulnerabilities. Among emerging therapeutic strategies, copper-based nanoparticles have shown anticancer activity. However, whether these responses differ across breast cancer subtypes and which molecular programs underlie copper sensitivity remain poorly understood. We investigated subtype-specific responses to Polyvinylpyrrolidone-assisted copper nanoparticles (CuNP-PVP) in breast cancer cell lines and the molecular programs underlying copper adaptation. CuNP-PVP were synthesized and evaluated in luminal (MCF-7), HER2-positive (SKBR3), and triple-negative (MDA-MB-231) breast cancer cell lines, with transcriptomic analyses integrated with CCLE and TCGA-BRCA datasets. UV-Vis spectroscopy revealed a plasmon resonance band at 591 nm, while TEM showed spherical nanoparticles with an average diameter of 76.1 ± 21.0 nm. DLS indicated a larger hydrodynamic diameter, consistent with PVP coating; ζ-potential measurements showed a surface charge of −13 mV, and XPS confirmed mixed reduced and Cu(I)/Cu(II) oxidation states. Exposure to 100 μg/mL CuNP-PVP induced subtype-dependent effects on cell viability, with MCF-7 showing greater sensitivity, whereas MDA-MB-231 and SKBR3 were less affected. Baseline transcriptomic analyses revealed enrichment of oxidative stress, metabolic adaptation, and lysosomal programs in less sensitive cells, whereas MCF-7 showed higher expression of lipoylation-related genes. These features supported the development of a Potential Biological Copper-Response Index (PBCRI), which captured subtype-associated transcriptional patterns across independent cell lines and patient tumors, with luminal models showing lower scores and basal/TNBC models showing higher scores. Together, these findings identify candidate transcriptional programs associated with subtype-specific responses to CuNP and provide a framework for investigating potential molecular determinants of copper sensitivity. Highlights: PVP-assisted copper nanoparticles showed mixed metallic/oxidized Cu phases. CuNP-PVP induced cell-dependent cytotoxicity in breast cancer cells. MCF-7 cells were more sensitive to CuNP-PVP than TNBC and HER2+ cells. Baseline profiles differed in lipoylation, antioxidant, and lysosomal programs. PBCRI captured subtype-associated copper-response transcriptional patterns.
- Open Access
Beyond Capture Efficiency: A Multidimensional Framework for Benchmarking Circulating Tumor Cell Isolation Technologies
Metastasis remains the major cause of cancer-related mortality, and circulating tumor cells (CTCs) are both candidate liquid-biopsy biomarkers and plausible intermediates of metastatic dissemination. Because CTCs are extremely rare in peripheral blood, platform comparisons have often focused solely on recovery. That focus is insufficient for applications that depend on the quality of the recovered material, including single-cell profiling, short-term culture, and functional testing. Here, we compared four CTC isolation approaches: TellDx CTC System, Genesis System, RosetteSep™, and flow cytometry, using spike-in experiments in human blood. Capture efficiency was evaluated across all four platforms; purity was assessed for TellDx, Genesis, and RosetteSep™; and post-isolation GFP signal persistence in culture was assessed for TellDx and Genesis as an exploratory proxy for short-term post-isolation preservation. Under the conditions tested, TellDx showed the highest recovery (88.1% ± 3.7%), followed by Genesis (40.6% ± 12.1%), RosetteSep™ (36.5% ± 9.0%), and flow cytometry (7.6% ± 4.5%). TellDx also showed the highest purity score (3.76), whereas Genesis (2.25) and RosetteSep™ (2.09) did not differ substantially. In the short-term culture assay, TellDx-derived samples retained a higher normalized GFP signal than Genesis-derived samples at 48 h and 72 h. To synthesize these readouts, we propose the Recovery Performance Index (RPI), a composite score integrating recovery, purity, and post-isolation signal persistence. Within this experimental framework, TellDx achieved the highest RPI. These data support two conclusions. First, platform benchmarking for CTC workflows benefits from multidimensional evaluation rather than recovery alone. Second, under this spike-in model and within the specific workflows used here, TellDx performed best among the platforms tested. The principal contribution of this study is therefore the establishment of a practical benchmarking framework that can be expanded in future work using clinical samples, multiple CTC phenotypes, and orthogonal viability assays.
Open AccessBeyond Capture Efficiency: A Multidimensional Framework for Benchmarking Circulating Tumor Cell Isolation Technologies
Metastasis remains the major cause of cancer-related mortality, and circulating tumor cells (CTCs) are both candidate liquid-biopsy biomarkers and plausible intermediates of metastatic dissemination. Because CTCs are extremely rare in peripheral blood, platform comparisons have often focused solely on recovery. That focus is insufficient for applications that depend on the quality of the recovered material, including single-cell profiling, short-term culture, and functional testing. Here, we compared four CTC isolation approaches: TellDx CTC System, Genesis System, RosetteSep™, and flow cytometry, using spike-in experiments in human blood. Capture efficiency was evaluated across all four platforms; purity was assessed for TellDx, Genesis, and RosetteSep™; and post-isolation GFP signal persistence in culture was assessed for TellDx and Genesis as an exploratory proxy for short-term post-isolation preservation. Under the conditions tested, TellDx showed the highest recovery (88.1% ± 3.7%), followed by Genesis (40.6% ± 12.1%), RosetteSep™ (36.5% ± 9.0%), and flow cytometry (7.6% ± 4.5%). TellDx also showed the highest purity score (3.76), whereas Genesis (2.25) and RosetteSep™ (2.09) did not differ substantially. In the short-term culture assay, TellDx-derived samples retained a higher normalized GFP signal than Genesis-derived samples at 48 h and 72 h. To synthesize these readouts, we propose the Recovery Performance Index (RPI), a composite score integrating recovery, purity, and post-isolation signal persistence. Within this experimental framework, TellDx achieved the highest RPI. These data support two conclusions. First, platform benchmarking for CTC workflows benefits from multidimensional evaluation rather than recovery alone. Second, under this spike-in model and within the specific workflows used here, TellDx performed best among the platforms tested. The principal contribution of this study is therefore the establishment of a practical benchmarking framework that can be expanded in future work using clinical samples, multiple CTC phenotypes, and orthogonal viability assays.
- Open Access
- 13 March 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1872 (5) , 168219
A control theoretical approach to gene regulation reveals quantitative constraints for dynamic homeostasis in stochastic gene expression
- 13 March 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1872 (5) , 168219
Open AccessA control theoretical approach to gene regulation reveals quantitative constraints for dynamic homeostasis in stochastic gene expression
- Open Access
- 14 May 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (20) , 20452-20464
Gold Nanoparticle-DNA Conjugates: An Enzymatic DNA Synthesis Platform
Leveraging the well-established properties of gold nanoparticle (AuNP)-DNA conjugates, this research explored a novel methodology for controlled enzymatic DNA synthesis using gold nanoparticle (AuNP)-DNA conjugates as a solid platform. To this end, Hybrid Nanoparticles (HNPs) were meticulously engineered through the functionalization of AuNPs with rationally designed DNA initiator molecules. These initiator molecules, strategically attached to the AuNP surface, served as a physical support and starting point for DNA extension by the Terminal Deoxynucleotidyl Transferase (TdT) enzyme. The results confirmed the synthesis of homopolymeric DNA extensions on these HNPs (58.27 nm, PDI < 0.2), demonstrating the viability of HNPs as a platform for enzymatic DNA elongation. Although the growing demand for data storage suggests a potential application, this research established the foundational feasibility of enzymatic DNA synthesis on HNPs. While high-density DNA data storage requires extensive development, the demonstrated enzymatic synthesis on AuNP-DNA conjugates warrants significant further exploration for future applications in biotechnology and nanotechnology.
- 14 May 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (20) , 20452-20464
Open AccessGold Nanoparticle-DNA Conjugates: An Enzymatic DNA Synthesis Platform
Leveraging the well-established properties of gold nanoparticle (AuNP)-DNA conjugates, this research explored a novel methodology for controlled enzymatic DNA synthesis using gold nanoparticle (AuNP)-DNA conjugates as a solid platform. To this end, Hybrid Nanoparticles (HNPs) were meticulously engineered through the functionalization of AuNPs with rationally designed DNA initiator molecules. These initiator molecules, strategically attached to the AuNP surface, served as a physical support and starting point for DNA extension by the Terminal Deoxynucleotidyl Transferase (TdT) enzyme. The results confirmed the synthesis of homopolymeric DNA extensions on these HNPs (58.27 nm, PDI < 0.2), demonstrating the viability of HNPs as a platform for enzymatic DNA elongation. Although the growing demand for data storage suggests a potential application, this research established the foundational feasibility of enzymatic DNA synthesis on HNPs. While high-density DNA data storage requires extensive development, the demonstrated enzymatic synthesis on AuNP-DNA conjugates warrants significant further exploration for future applications in biotechnology and nanotechnology.
- 29 January 2024
- Published by Taylor & Francis in Nanomedicine
- Vol. 19 (3) , 231-254
HER2 Aptamer-Conjugated Iron Oxide Nanoparticles with PDMAEMA-b-PMPC Coating for Breast Cancer Cell Identification
Aim: To synthesize HER2 aptamer-conjugated iron oxide nanoparticles with a coating of poly(2-(dimethylamino) ethyl methacrylate)–poly(2-methacryloyloxyethylphosphorylcholine) block copolymer (IONPP...
- 29 January 2024
- Published by Taylor & Francis in Nanomedicine
- Vol. 19 (3) , 231-254
HER2 Aptamer-Conjugated Iron Oxide Nanoparticles with PDMAEMA-b-PMPC Coating for Breast Cancer Cell Identification
Aim: To synthesize HER2 aptamer-conjugated iron oxide nanoparticles with a coating of poly(2-(dimethylamino) ethyl methacrylate)–poly(2-methacryloyloxyethylphosphorylcholine) block copolymer (IONPP...
- Open Access
Machine Learning Model to Predict Allocation of Patients with Chronic Back Pain for Integrated Practice Units in a System of Value-based Health Care
Chronic pain incurs substantial global healthcare costs, requiring long-term specialized care. However, the variability in treatment approaches hampers the feasibility of value-based healthcare. To advance management and prevention efforts, data science tools like supervised and unsupervised machine learning algorithms offer promising solutions. This study employed data from six questionnaires to evaluate pain conditions in patients. Correlation techniques were applied to determine the questions most strongly correlated with low back pain, back pain, and leg pain. Five machine learning algorithms predicted the presence or absence of pain in the low back region. Seven variables were identified as input for the prediction models, with the XBoost Classifier demonstrating the highest accuracy, precision, recall, and F1-Score (0.8 accuracy, precision, recall; 0.78 F1-Score). By incorporating the machine learning model, it predicts the allocation of chronic back pain patients to integrated practice in a value-based healthcare system. Finally, our findings show that data science methods, such as machine learning, improve chronic pain management, expedite surveys, and improve value-based healthcare through efficient allocation. Highlights Correlation analysis identified pain-related questions (back, leg, chronic low back). 7 characteristics used by ML algorithms to forecast chronic low back pain occurrence. XBoost algorithm and neural network achieved best performance (Precision, Recall ∼0.8). Outcomes aid patient allocation, screening, and reducing costs in value-based healthcare. Streamlining surveys boosts response rates and enables larger datasets for improved modeling.
Open AccessMachine Learning Model to Predict Allocation of Patients with Chronic Back Pain for Integrated Practice Units in a System of Value-based Health Care
Chronic pain incurs substantial global healthcare costs, requiring long-term specialized care. However, the variability in treatment approaches hampers the feasibility of value-based healthcare. To advance management and prevention efforts, data science tools like supervised and unsupervised machine learning algorithms offer promising solutions. This study employed data from six questionnaires to evaluate pain conditions in patients. Correlation techniques were applied to determine the questions most strongly correlated with low back pain, back pain, and leg pain. Five machine learning algorithms predicted the presence or absence of pain in the low back region. Seven variables were identified as input for the prediction models, with the XBoost Classifier demonstrating the highest accuracy, precision, recall, and F1-Score (0.8 accuracy, precision, recall; 0.78 F1-Score). By incorporating the machine learning model, it predicts the allocation of chronic back pain patients to integrated practice in a value-based healthcare system. Finally, our findings show that data science methods, such as machine learning, improve chronic pain management, expedite surveys, and improve value-based healthcare through efficient allocation. Highlights Correlation analysis identified pain-related questions (back, leg, chronic low back). 7 characteristics used by ML algorithms to forecast chronic low back pain occurrence. XBoost algorithm and neural network achieved best performance (Precision, Recall ∼0.8). Outcomes aid patient allocation, screening, and reducing costs in value-based healthcare. Streamlining surveys boosts response rates and enables larger datasets for improved modeling.
- Open Access
Iron Oxide Nanoparticles Coated with Biodegradable Block-Copolymer PDMAEMA-b-PMPC and Functionalized with Aptamer for HER2 Breast Cancer Cell Identification
Hybrid nanoparticles have shown promise in biomedical applications; however, their seamless integration into clinical settings remains challenging. Here, we introduce a novel metal oxide polymer hybrid nanoparticle (NP) with a high affinity for nucleic acids. Iron oxide nanoparticles (IONP) were initially synthesized via the co-precipitation method and subjected to comprehensive characterization. Subsequently, block copolymers were synthesized using the Reversible Addition−Fragmentation Chain Transfer (RAFT) technique, employing the zwitterionic PMPC (Poly (2 Methacryloyloxyethyl Phosphorylcholine)) and the cationic PDMAEMA (Poly(2 (Dimethylamino) Ethyl Methacrylate)) with varying degrees of polymerization. In vitro cytotoxicity studies demonstrated the biocompatibility of the synthesized nanoparticles, with no observed toxicity up to a concentration of 150 µg/mL. The cationic polymer PDMAEMA facilitated the facile coating of IONP, forming the IONPP complex, consisting of a 13.27 metal core and a 3.1 nm block-copolymer coating. Subsequently, the IONPP complex was functionalized with a DNA aptamer specifically targeting the human epidermal growth factor receptor 2 (HER2) in breast cancer, forming IONPPP. The block-copolymer exhibited an EC 50 of 7.07 µg/mL and demonstrated enhanced recognition efficiency in HER2-amplified SKBR3 cells. Our study presents a comprehensive IONPPP characterization capable of binding short DNA sequences and targeting proteins such as HER2. This newly developed nanoparticle holds significant potential for cancer cell identification and isolation, offering promising prospects in cancer research and clinical applications. 1. Statement of significance: Despite recent advancements in biomedical research, developing sensitive and specific tools for recognizing biological motifs, such as cell receptors and proteins in complex biological solutions, remains a challenge. Furthermore, current approaches often rely on complex biological derivatives like antibodies, lacking a cost-effective delivery strategy. Our study proposes creating and characterizing a novel hybrid metal oxide polymer nanoparticle named IONPPP, functionalized with a DNA aptamer designed to recognize HER2-positive cells. HER2 is a clinically actionable marker for gastric, gastroesophageal, and, particularly, breast cancers. This unique combination of a metal core with an external polymeric structure offers the potential for identification, isolation, and even theragnostic applications, benefiting from its low toxicity and high specificity. 2. Graphical
Open AccessIron Oxide Nanoparticles Coated with Biodegradable Block-Copolymer PDMAEMA-b-PMPC and Functionalized with Aptamer for HER2 Breast Cancer Cell Identification
Hybrid nanoparticles have shown promise in biomedical applications; however, their seamless integration into clinical settings remains challenging. Here, we introduce a novel metal oxide polymer hybrid nanoparticle (NP) with a high affinity for nucleic acids. Iron oxide nanoparticles (IONP) were initially synthesized via the co-precipitation method and subjected to comprehensive characterization. Subsequently, block copolymers were synthesized using the Reversible Addition−Fragmentation Chain Transfer (RAFT) technique, employing the zwitterionic PMPC (Poly (2 Methacryloyloxyethyl Phosphorylcholine)) and the cationic PDMAEMA (Poly(2 (Dimethylamino) Ethyl Methacrylate)) with varying degrees of polymerization. In vitro cytotoxicity studies demonstrated the biocompatibility of the synthesized nanoparticles, with no observed toxicity up to a concentration of 150 µg/mL. The cationic polymer PDMAEMA facilitated the facile coating of IONP, forming the IONPP complex, consisting of a 13.27 metal core and a 3.1 nm block-copolymer coating. Subsequently, the IONPP complex was functionalized with a DNA aptamer specifically targeting the human epidermal growth factor receptor 2 (HER2) in breast cancer, forming IONPPP. The block-copolymer exhibited an EC 50 of 7.07 µg/mL and demonstrated enhanced recognition efficiency in HER2-amplified SKBR3 cells. Our study presents a comprehensive IONPPP characterization capable of binding short DNA sequences and targeting proteins such as HER2. This newly developed nanoparticle holds significant potential for cancer cell identification and isolation, offering promising prospects in cancer research and clinical applications. 1. Statement of significance: Despite recent advancements in biomedical research, developing sensitive and specific tools for recognizing biological motifs, such as cell receptors and proteins in complex biological solutions, remains a challenge. Furthermore, current approaches often rely on complex biological derivatives like antibodies, lacking a cost-effective delivery strategy. Our study proposes creating and characterizing a novel hybrid metal oxide polymer nanoparticle named IONPPP, functionalized with a DNA aptamer designed to recognize HER2-positive cells. HER2 is a clinically actionable marker for gastric, gastroesophageal, and, particularly, breast cancers. This unique combination of a metal core with an external polymeric structure offers the potential for identification, isolation, and even theragnostic applications, benefiting from its low toxicity and high specificity. 2. Graphical
- Open Access
- 9 May 2023
- Published by Center for Open Science in OSF Preprints
The Descriptive and Analytical Epidemiology of Glioblastoma Worldwide: an Informative Science Review
This descriptive narrative review demonstrates state-of-the-art epidemiological research in glioblastoma (GB). We discussed the case number and deaths worldwide and the intrinsic and extrinsic risk factors (RF) in cancer analytical epidemiology. GB is the most common glioma, with increased cases in recent decades. Despite much research in the last decades, GB is a disease with a poor survival prognosis. The difference in the amount of data between developed and other countries is notable, as shown in our review. Many intrinsic and extrinsic RF have been studied for GB in recent years, resulting in few conclusions, with cases being more common in older, white, and male patients. In contrast to other review articles, which include more than one neuro-oncological disease, this paper concentrates on GB epidemiological data, including neglected countries. Moreover, we demonstrate and discuss GB’s most recent molecular classification for discovering new molecular markers for prognosis and treatment. More studies are needed to understand extrinsic RF and elucidate contradictory results from the literature. While highlighting the differences between developed and in-development countries, this review can provide grounds for future research in neglected regions, helping improve the quality of living in GB patients.
- 9 May 2023
- Published by Center for Open Science in OSF Preprints
Open AccessThe Descriptive and Analytical Epidemiology of Glioblastoma Worldwide: an Informative Science Review
This descriptive narrative review demonstrates state-of-the-art epidemiological research in glioblastoma (GB). We discussed the case number and deaths worldwide and the intrinsic and extrinsic risk factors (RF) in cancer analytical epidemiology. GB is the most common glioma, with increased cases in recent decades. Despite much research in the last decades, GB is a disease with a poor survival prognosis. The difference in the amount of data between developed and other countries is notable, as shown in our review. Many intrinsic and extrinsic RF have been studied for GB in recent years, resulting in few conclusions, with cases being more common in older, white, and male patients. In contrast to other review articles, which include more than one neuro-oncological disease, this paper concentrates on GB epidemiological data, including neglected countries. Moreover, we demonstrate and discuss GB’s most recent molecular classification for discovering new molecular markers for prognosis and treatment. More studies are needed to understand extrinsic RF and elucidate contradictory results from the literature. While highlighting the differences between developed and in-development countries, this review can provide grounds for future research in neglected regions, helping improve the quality of living in GB patients.